ABBV
ABBV clinical trials: AbbVie Inc.
Every trial on ClinicalTrials.gov where AbbVie Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 2,427
- Trials linked
- 1,843
- As lead sponsor
- 584
- As collaborator
- 15
- Primary completions as lead sponsor, next 90 days
ABBV on the catalyst calendar · ABBV registry changes
- Primary completion Jun 2035Sponsor estimatePhase 2/Phase 3NCT07933211A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic...AbbVie · Systemic SclerosisNot yet recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 3NCT04777357A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in...AbbVie · DepressionRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2033Sponsor estimatePhase 3NCT07728188A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard...AbbVie · Relapsed or Refractory Multiple MyelomaRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 20, 2025ActualPhase 3NCT06068855A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult...AbbVie · Masseter Muscle ProminenceCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 13, 2026ActualPhase 2NCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)AbbVie · Neovascular Age-Related Macular Degeneration (nAMD)Active, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2026ActualPhase 1NCT07680686Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsAbbVie · Healthy VolunteerCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2025ActualNo phase registeredNCT06937034Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's DiseaseAbbVie · Parkinson's DiseaseCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 18, 2026ActualPhase 2NCT04567550RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center...AbbVie · Diabetic Retinopathy (DR)CompletedABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2026ActualNo phase registeredNCT06023030An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to...AbbVie · Crohn's DiseaseCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 3NCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate...AbbVie · Hidradenitis SuppurativaActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1NCT07935564A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants.AbbVie · Healthy VolunteerNot yet recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2NCT07933536A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe PsoriasisAbbVie · Moderate to Severe PsoriasisNot yet recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimateEarly Phase 1NCT07933497M4 Receptor PET Radioligand Validation Study in Healthy AdultsAbbVie · Healthy VolunteersNot yet recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 2NCT07904754Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisAbbVie · Rheumatoid ArthritisNot yet recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2027Sponsor estimateNo phase registeredNCT07227896Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson...AbbVie · Parkinson's DiseaseRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 1NCT05650632A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory...AbbVie · Multiple MyelomaRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT07925983A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult ParticipantsAbbVie · Healthy VolunteerRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07514260A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese...AbbVie · Healthy VolunteerActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 2NCT06865105Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisAbbVie · Psoriatic ArthritisRecruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2026ActualNo phase registeredNCT05827887An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult ParticipantsAbbVie · MigraineCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2031Sponsor estimatePhase 2NCT05296447Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyAbbVie · Diabetic Retinopathy, DRActive, not recruitingABBVLeadRGNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 5, 2026ActualPhase 1NCT07649954A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsAbbVie · Healthy VolunteerCompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07291232A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityAbbVie · ObesityActive, not recruitingABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2025ActualPhase 2NCT06032546A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With...AbbVie · Human Immuno-deficiency Virus (HIV) DiseaseTerminatedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2026ActualNo phase registeredNCT05959083Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese...AbbVie · Atopic Dermatitis (AD)CompletedABBVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 2,402 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner